Last reviewed · How we verify
Dextromethorphan 5 MG
At a glance
| Generic name | Dextromethorphan 5 MG |
|---|---|
| Sponsor | Jules Desmeules |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Psychedelics in Healthy Older Adults With Low Well-being (PHASE1)
- A Study in Healthy Participants to Evaluate the Effects of Multiple Doses of JNJ-55308942 on Cytochrome P450 Substrate Activity and on the Pharmacokinetics of Levonorgestrel/Ethinyl Estradiol (PHASE1)
- Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach (EARLY_PHASE1)
- Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product (EARLY_PHASE1)
- DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan (PHASE1)
- Licorice Botanical Dietary Supplements - Metabolism and Safety in Women (PHASE1)
- Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (PHASE3)
- Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dextromethorphan 5 MG CI brief — competitive landscape report
- Dextromethorphan 5 MG updates RSS · CI watch RSS
- Jules Desmeules portfolio CI